Medpace Holdings Inc (MEDP)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Medpace Holdings Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 577.10 $ — 81% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 20.1% passed
- More than 10% revenue growth is expected for the coming year 6.2% failed
- Share count grows by less than 3% a year -4.3% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 46.9% passed
- Gross margin at 40% or higher and without meaningful erosion 30.1% failed
- Goodwill from acquisitions does not grow faster than revenue 33.5% passed
- Net debt below twice EBITDA 247 m net cash passed
- Operating cash flow covers the profits of the last three years 617 m passed
- Return on capital at 15% or higher, or up versus two years ago 84.7% passed
- Insiders hold at least 10% or are net buyers 19.4% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 0.8% above the current price.
- Consensus
- Hold
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 17.70 | 17.49 – 18.37 | 2,852 | 15.9% | 10 |
| 12/31/2027 | 19.31 | 17.60 – 20.16 | 3,027 | 9.1% | 10 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.44 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 3.66 | 48.60 | 537 | 7.70 | 21.80 | 191 | 183 |
| 2025: Q1 | 3.67 | 14.60 | 559 | 9.30 | 20.50 | 126 | 116 |
| 2025: Q2 | 3.10 | 12.70 | 603 | 14.20 | 15.00 | 149 | 142 |
| 2025: Q3 | 3.86 | 28.20 | 660 | 23.70 | 16.80 | 246 | 262 |
| 2025: Q4 | 4.67 | 27.60 | 709 | 32.00 | 19.10 | 193 | 188 |
| 2026: Q1 | 4.28 | 16.40 | 707 | 26.50 | 17.50 | 152 | 145 |
| 2026: Q2 | 4.25 | 37.10 | 707 | 17.20 | 17.20 | 162 | 138 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 422 | 52 | 13 | 0.37 | 92 | 611 | 979 |
| 2017 | 436 | 65 | 39 | 0.98 | 97 | 504 | 951 |
| 2018 | 705 | 101 | 73 | 1.98 | 157 | 590 | 968 |
| 2019 | 861 | 127 | 100 | 2.67 | 202 | 726 | 1,143 |
| 2020 | 926 | 167 | 145 | 3.86 | 259 | 806 | 1,391 |
| 2021 | 1,142 | 199 | 182 | 4.82 | 263 | 953 | 1,660 |
| 2022 | 1,460 | 279 | 245 | 7.29 | 388 | 386 | 1,353 |
| 2023 | 1,886 | 337 | 283 | 8.88 | 433 | 559 | 1,657 |
| 2024 | 2,109 | 447 | 404 | 12.63 | 609 | 826 | 2,101 |
| 2025 | 2,530 | 535 | 451 | 15.28 | 713 | 459 | 1,975 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Medpace Holdings, Inc. bietet klinisch-forschungsbasierte Dienste für die Entwicklung von Arzneimitteln und Medizinprodukten in Nordamerika, Europa, Asien, Südamerika, Afrika und Australien an.
| Employees | 6,500 |
|---|---|
| Headquarters | Cincinnati, OH |
| Address | 5375 Medpace Way, 45227 Cincinnati, United States |
| Phone | 513 579 9911 |
| Website | medpace.com |
| IPO Date | 11. Aug 2016 |
| ISIN | US58506Q1094 |
Management
| Name | Title | Birth Year |
|---|---|---|
| August James Troendle M.D. | CEO, President & Chairman | 1956 |
| Kevin M. Brady | CFO & Treasurer | 1975 |
| Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 1969 |
| Brad W. Hansman | Executive Vice President of Operations | 1983 |
| Lauren Morris | Associate Director of Investors Relations | – |
| Todd Meyers | Vice President of Business Development & Marketing | – |
| Weimin Gai MS | Senior Vice President of Biometrics | – |
| John T. Wynne MBA | Chief Business Officer | – |
| Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 1961 |
| Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | Burwig Susan E | Exec. VP, Operations | Sell | 7,500 | 600.00 | 4,500,000 |
| 28. Jul 2026 | Troendle August J. | President & CEO | Sell | 3,510 | 600.01 | 2,106,035 |
| 27. Jul 2026 | Troendle August J. | President & CEO | Sell | 3,728 | 600.85 | 2,239,969 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.